AstraZeneca - HER tomorrow in HER2+ metastatic breast cancer
HER new potential: New advances in HER2+ breast cancer treatment
Date
22 Sep 2020Session
AstraZeneca - HER tomorrow in HER2+ metastatic breast cancerPresenters
Erika HamiltonAuthors
E.P. HamiltonAuthor affiliations
- Drug Development Unit, Sarah Cannon Research Institute-Cancer Centre, 37203 - Nashville/US
Resources
Resources from the same session
Welcome and introductions
Presenter: Eva Ciruelos
Session: AstraZeneca - HER tomorrow in HER2+ metastatic breast cancer
Resources:
Webcast
HER past: Looking back on two decades of HER2-targeted therapy
Presenter: Fatima Cardoso
Session: AstraZeneca - HER tomorrow in HER2+ metastatic breast cancer
Resources:
Webcast
Sharing HER experience: Case-based panel discussion
Presenter: Erika Hamilton
Session: AstraZeneca - HER tomorrow in HER2+ metastatic breast cancer
Resources:
Webcast
Closing remarks
Presenter: Eva Ciruelos
Session: AstraZeneca - HER tomorrow in HER2+ metastatic breast cancer
Resources:
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.